Murat Günaltılı

14PUBLICATIONS
37CO-AUTHORS
Respiratory diseasesHaematological tumoursMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Immunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Sep 26, 2026
Prognostic Value of the Royal Marsden Hospital Score in Patients with De Novo Metastatic Colorectal Cancer Receiving First-Line Systemic Therapy.

|Jul 15, 2026
Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study.

|Jun 16, 2026
Association between obesity and outcomes of first-line CDK4/6 inhibitor therapy in metastatic breast cancer: a multicenter real-world study.

|May 27, 2026
Prognostic Impact of PET/CT-Derived Sarcopenia in Metastatic Breast Cancer Treated with CDK4/6 Inhibitors.

|May 06, 2026
Immune-Mediated upper gastrointestinal toxicities reported With immune checkpoint inhibitors: An analysis of the food and drug administration adverse event reporting system (FAERS).

|May 04, 2026
Oligoprogression During First-Line Treatment of Metastatic Hormone-Sensitive Prostate Cancer: Comparative Outcomes of Metastasis-Directed Radiotherapy and Systemic Treatment Change.

Pageof 3

Frequent Collaborators

11 joint publications

Özkan Alan

8 joint publications

Seda Jeral Evinç

8 joint publications

Hamza Abbasov

6 joint publications

Murad Guliyev